Food Allergy Clinical Trials
Here are the 6 most popular medical studies for food allergy
Immunotherapy
Multi OIT +1 More for Food Allergy
The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.
Herbal Medicine
FAHF-2 (TM) for Food Allergy
The increasing prevalence of allergic diseases in westernized countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to peanut, tree nuts, sesame, fish, and/or shellfish.
Popular filter options for food allergy trials
Peanut Allergy Clinical Trials
View 8 Peanut Allergy medical studies.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Food Allergy Clinical Trials With No Placebo
View 22 food allergy medical studies that do not have a placebo group.
Behavioral Intervention
Food Allergy Mastery Program for Food Allergies
This trial will examine a new program to help teens with food allergies learn how to manage their condition, with education, problem-solving, communication, and peer support.
Behavioural Intervention
TEWL Monitoring for Peanut Allergy Anaphylaxis Prevention
This trial tests a new way to detect early signs of anaphylaxis in peanut allergy patients during food challenges. It uses a sensor to monitor skin water loss to end the challenge before symptoms appear.
View More Food Allergy Trials
See another 3 medical studies focused on food allergy.
Frequently Asked Questions
Introduction to food allergy
What are the top hospitals conducting food allergy research?
When it comes to advancing our understanding and treatment of food allergies, several leading hospitals are at the forefront of clinical trials. In New york City, the Icahn School of Medicine at Mount Sinai is making significant strides with three ongoing food allergy trials. While they have only recorded one trial in this field thus far, their commitment to research and innovation is evident. Boston's Massachusetts General Hospital also plays a crucial role in this arena, currently conducting two active food allergy trials. Although they do not have any previous recorded trials specifically focused on food allergies, their expertise and resources make them an important contributor to the field.
Heading down south to Washington D.C., Childrens' National Hospital is dedicated to improving our understanding of food allergies through one ongoing clinical trial. Similarly, Novartis Investigative Site in Ypsilanti and San Jose are each engaged in advancing knowledge about food allergies with one active trial each.
These institutions across different locations signify the collective effort being made towards unraveling the complexities surrounding food allergies—a condition that affects millions worldwide. By conducting these essential clinical trials, researchers aim to find novel treatments and therapies that can alleviate symptoms or even prevent allergic reactions altogether. The dedication shown by these hospitals underscores not just their commitment but also their profound compassion for those living with this challenging medical condition—and gives hope for a future where individuals can enjoy meals without fear or restriction
Which are the best cities for food allergy clinical trials?
New york, New York; Boston, Massachusetts; and Baltimore, Maryland emerge as the most promising cities for food allergy clinical trials. These locations offer a range of ongoing studies focused on various treatments such as Ligelizumab 120 mg, Abrocitinib 100mg, peanut oral immunotherapy, and more. With five active trials in New York City, four in Boston, and three in Baltimore—all investigating innovative approaches to managing food allergies—these cities provide individuals with opportunities to participate in cutting-edge research that may pave the way for improved treatment options and enhanced quality of life.
Which are the top treatments for food allergy being explored in clinical trials?
When it comes to the exploration of treatments for food allergy in clinical trials, there are a few standout contenders. One such treatment being investigated is oral immunotherapy, which involves gradually introducing small amounts of the allergen into the patient's diet to build tolerance. Another promising avenue is sublingual immunotherapy, where drops or tablets containing extracts of the allergen are placed under the tongue. These approaches aim to desensitize individuals and reduce allergic reactions over time. Exciting advancements are also being made with biologics, specifically anti-IgE antibodies that target and neutralize allergic responses. With ongoing research and development in these areas, hope continues to grow for effective solutions to combat food allergies.
What are the most recent clinical trials for food allergy?
Significant progress is being made in the field of food allergy research, with recent clinical trials offering promising insights into potential treatments. One such trial investigated the use of antibiotics combined with microbiota-targeted therapy (MTT) in managing food allergies. The results from this Phase 2 study demonstrated encouraging outcomes for patients. Additionally, a Phase 3 trial evaluated ligelizumab at a dosage of 120 mg as a treatment option for food allergy sufferers. Another noteworthy trial explored abrocitinib at a strength of 100mg and its efficacy in addressing food allergies during its Phase 1 stage. Finally, two trials—ADP101 and prebiotic—have shown positive developments during their respective Phase 1 and Phase 2 stages. These exciting clinical trials offer hope to those living with food allergies, indicating advancements in understanding and potentially mitigating allergic responses to certain foods.
What food allergy clinical trials were recently completed?
A recently completed clinical trial focused on food allergies highlights the ongoing efforts to advance treatments in this field. In December 2021, Johns Hopkins University successfully wrapped up a trial investigating Acalabrutinib's potential impact on food allergy management. This study constitutes an important step forward in our understanding of how to address and potentially alleviate the challenges faced by individuals with food allergies. The findings of this trial contribute valuable insights that may pave the way for improved therapies and enhanced quality of life for those affected by these conditions.